Pharmacokinetics and metabolism of thioridazine during co‐administration of tricyclic antidepressants
- 1 September 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 131 (2) , 287-295
- https://doi.org/10.1038/sj.bjp.0703540
Abstract
Because of serious side‐effects of thioridazine and tricyclic antidepressants (cardiotoxicity), a possible influence of imipramine and amitriptyline on the pharmacokinetics and metabolism of thioridazine was investigated in a steady state (2‐week treatment) in rats. Imipramine and amitriptyline (5 and 10 mg kg−1 i.p., respectively) elevated 30 and 20 fold, respectively, the concentration of thioridazine (10 mg kg−1 i.p.) and its metabolites (N‐desmethylthioridazine, 2‐sulphoxide, 2‐sulphone, 5‐sulphoxide) in blood plasma. Similar, yet weaker increases in the thioridazine concentration were found in the brain. Moreover, an elevation of thioridazine/metabolite ratios was observed. Imipramine and amitriptyline added to control liver microsomes in vitro inhibited the metabolism of thioridazine via N‐demethylation (an increase in Km), mono‐2‐sulphoxidation (an increase in Km and a decrease in Vmax) and 5‐sulphoxidation (mainly a decrease in Vmax). Amitriptyline was a more potent inhibitor than imipramine of the thioridazine metabolism. The varying concentration ratios of antidepressant/thioridazine in vivo appear to be more important to the final result of the pharmacokinetic interactions than are relative direct inhibitory effects of the antidepressants on thioridazine metabolism observed in vitro. Besides direct inhibition of the thioridazine metabolism, the decreased activity of cytochrome P‐450 towards 5‐sulphoxidation, produced by chronic joint administration of thioridazine and the antidepressants, seems to be relevant to the observed in vivo interaction. The obtained results may also point to inhibition of another, not yet investigated, metabolic pathway of thioridazine, which may be inferred from the simultaneous elevation of concentrations of both thioridazine and the measured metabolites. British Journal of Pharmacology (2000) 131, 287–295; doi:10.1038/sj.bjp.0703540Keywords
This publication has 49 references indexed in Scilit:
- Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half-life repeated administrations to ratsGeneral Pharmacology: The Vascular System, 1996
- Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenaseXenobiotica, 1995
- Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or AmitriptylineTherapeutic Drug Monitoring, 1992
- Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heartToxicology and Applied Pharmacology, 1986
- Phenolic metabolites of thioridazine in manXenobiotica, 1985
- Distribution of chlorpromazine and imipramine in adipose and other tissues of ratsLife Sciences, 1983
- Interaction of Chlorpromazine and Nortriptyline in Patients with SchizophreniaClinical Pharmacokinetics, 1981
- Plasma Concentrations of Thioridazine Metabolites and ECG AbnormalitiesJournal of Pharmaceutical Sciences, 1978
- Pharmacokinetic Interaction between Amitriptyline and NeurolepticsNeuropsychobiology, 1978
- Binding of basic and acidic drugs to rat tissue subcellular fractionsChemico-Biological Interactions, 1974